Event: Pfizer MPP announced that covid-19 oral drug authorized manufacturers have signed agreements with 35 pharmaceutical enterprises
According to the Shanghai Securities News, sina finance and other media, on March 17, the Geneva pharmaceutical patent pool (MPP) announced that 35 companies had signed an agreement to produce nimatrilvir, one of the components of Pfizer covid-19 oral drug paxlovid. These manufacturers were allowed to produce the API or preparation of nimatrilvir. Among the 35 enterprises, 5 are Chinese enterprises, including Apeloa Pharmaceutical Co.Ltd(000739) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Shanghai Desano and Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) . Among them, Apeloa Pharmaceutical Co.Ltd(000739) and Kyushu pharmaceutical only produce relevant APIs. The agreement indicates that qualified non generic drug companies licensed worldwide will be able to provide paxlovid covid-19 therapy to 95 countries around the world, covering about 53% of the global population, including all low-income and middle-income countries in sub Saharan Africa, as well as some middle-income and high-income countries, as well as countries from low-income to middle-income to high-income in the past five years. Previously, on January 20, 27 generic drug manufacturers also signed an agreement with the drug patent pool to produce a low-cost version of mosadon covid-19 oral drug molnupiravir, which will be supplied in 105 low-income countries and regions around the world. Among the 27 enterprises that have signed the agreement, 5 are Chinese enterprises, including Brightgene Bio-Medical Technology Co.Ltd(688166) , Shanghai Desano, Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Langhua pharmaceutical and Longze pharmaceutical.
At present, the covid-19 pneumonia epidemic still has high uncertainty, and the demand for covid-19 treatment is also relatively clear. The recent imitation authorization of covid-19 oral medicine by MSD and Pfizer is the external embodiment of the global market demand. Covid-19 oral medicine, as the last puzzle in the covid-19 treatment industry chain, has a broad market prospect. In the special report on covid-19 epidemic situation in November last year, the annual strategy report and the weekly report since the beginning of the year, we have repeatedly pointed out the investment opportunities of covid-19 oral drug industry chain, and the market trend has verified our judgment. With the stability of the popular track and the current situation that the pharmaceutical industry has no clear direction in the short term, combined with the release of the ninth edition of treatment guidelines, it is suggested to continue to pay attention to the investment opportunities of covid-19 small molecule drug industry chain, and pay attention to the listed companies deeply involved in covid-19 prevention and treatment drug supply chain.
Suggested concern
Upstream investment opportunities of covid-19 treatment industry chain: benefit from the upstream API suppliers of covid-19 treatment authorized by MMP, such as Apeloa Pharmaceutical Co.Ltd(000739) , Zhe Jiang Hua Hai Pharmaceuticalco.Ltd(600521) , Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) , Shanghai Fosun Pharmaceutical (Group) Co.Ltd(600196) , Aba Chemicals Corporation(300261) , Ningbo Menovo Pharmaceutical Co.Ltd(603538) and Zhejiang Tianyu Pharmaceutical Co.Ltd(300702) .
Investment opportunities in the midstream of covid-19 treatment industry chain: covid-19 treatment drug manufacturers with outstanding R & D capabilities, including oral drugs and antibody related enterprises, such as Shanghai Junshi Biosciences Co.Ltd(688180) -u, Wuxi Apptec Co.Ltd(603259) and tengshengbo-b.
Covid-19 downstream industrial chain investment opportunities: China Meheco Group Co.Ltd(600056) ;
Relevant enterprises of Chinese patent medicine included in covid-19 diagnosis and treatment plan: Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) , Shandong Buchang Pharmaceuticals Co.Ltd(603858) etc;
Listed companies deeply involved in covid-19 prevention and treatment drug supply chain: Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Porton Pharma Solutions Ltd(300363) , etc.
Risk tips
Epidemic risk, policy risk, increased friction between China and the United States, and the risk that R & D is less than expected
